ZURICH (Reuters) – Roche announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company’s bispecific antibody Glofitamab. Glofitamab is intended for patients …
ZURICH (Reuters) – Roche announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company’s bispecific antibody Glofitamab. Glofitamab is intended for patients …